Galectin files belapectin Phase 3 protocol with FDA as chairman converts $105.8M debt
The company says it has submitted a registrational protocol for belapectin in MASH cirrhosis with portal hypertension, and reports cash it expects to last through June 2027.
Galectin Therapeutics has filed with the US Food and Drug Administration the protocol for a registrational Phase 3 trial of belapectin in patients with MASH cirrhosis and portal hypertension. The company announced the submission with its third-quarter 2026 results on 16 November 2026, covering the quarter ended 30 September.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Galectin Therapeutics Inc ↗
Article written by VigiEye from the official source (Galectin Therapeutics Inc). Claims are the company's own. AI-assisted; check the source before acting.